Affymetrix

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article needs to be updated. Please help update this article to reflect recent events or newly available information. (March 2020) A major contributor to this article appears to have a close connection with its subject. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. Please discuss further on the talk page. (January 2015) (Learn how and when to remove this message) This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Affymetrix" – news · newspapers · books · scholar · JSTOR (March 2020) (Learn how and when to remove this message) This article has an unclear citation style. The references used may be made clearer with a different or consistent style of citation and footnoting. (March 2020) (Learn how and when to remove this message) (Learn how and when to remove this message)

Affymetrix, Inc.

Company type	Subsidiary
Industry	Biotechnology
Founded	1992
Headquarters	Santa Clara, California, U.S.
Number of locations	11
Key people	Stephen Fodor, Frank Witney (CEO)
Revenue	US$327 Million (FY 2009)[1]
Operating income	US$-30.6 Million (FY 2009)[1]
Net income	US$-23.9 Million (FY 2009)[1]
Total assets	US$612 Million (FY 2009)[2]
Total equity	US$288 Million (FY 2009)[2]
Number of employees	1,141[3]
Parent	Thermo Fisher Scientific
Website	https://www.thermofisher.com/us/en/home/life-science/microarray-analysis.html

Affymetrix is now Applied Biosystems, a brand of DNA microarray products sold by Thermo Fisher Scientific that originated with an American biotechnology research and development and manufacturing company of the same name.^[4] The Santa Clara, California-based Affymetrix, Inc. now a part of Thermo Fisher Scientific was co-founded by Alex Zaffaroni and Stephen Fodor. Stephen Fodor and his group, based on their earlier development of methods to fabricate DNA microarrays using semiconductor manufacturing techniques.^[5][6]

In 1994, the company's first product under the "GeneChip" Affymetrix trademark, an HIV genotyping chip was introduced,^[7] and the company went public in 1996.^[8]

After incorporation, Affymetrix grew in part by acquiring technologies from other companies, including Genetic MicroSystems (slide-based Microarrays and scanners)^{[citation needed]} and Neomorphic (for bioinformatics) in 2000,^[9] ParAllele Bioscience (custom SNP genotyping),^{[citation needed]} USB/Anatrace (biochemical reagents) in 2008,^[10] Panomics (low to mid-plex applications) in 2008,^{[citation needed]} and eBioscience (flow cytometry) in 2012.^[11] Affymetrix spun off Perlegen Sciences,^[12][when?] as a discrete business focusing on wafer-scale genomics to characterize population-variance of genomic markers.^[13]

In January 2014, the Food and Drug Administration approved Affymetrix's postnatal blood test, CytoScan Dx Assay, looking at whole-genome correlates of congenital abnormalities and other causes of childhood developmental delay.^[14]

On January 8, 2016, Thermo Fisher Scientific announced its acquisition of Affymetrix for approximately $1.3 billion,^[15] which closed on March 31, 2016.^[16]